Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.
2.

HIV-1 genotypic zidovudine drug resistance and the risk of maternal--infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group.

Welles SL, Pitt J, Colgrove R, McIntosh K, Chung PH, Colson A, Lockman S, Fowler MG, Hanson C, Landesman S, Moye J, Rich KC, Zorrilla C, Japour AJ.

AIDS. 2000 Feb 18;14(3):263-71.

PMID:
10716502
3.

Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Sperling RS, Shapiro DE, Coombs RW, Todd JA, Herman SA, McSherry GD, O'Sullivan MJ, Van Dyke RB, Jimenez E, Rouzioux C, Flynn PM, Sullivan JL.

N Engl J Med. 1996 Nov 28;335(22):1621-9.

4.

Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team.

Mofenson LM, Lambert JS, Stiehm ER, Bethel J, Meyer WA 3rd, Whitehouse J, Moye J Jr, Reichelderfer P, Harris DR, Fowler MG, Mathieson BJ, Nemo GJ.

N Engl J Med. 1999 Aug 5;341(6):385-93.

5.

Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.

Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, Becquet R, Viho I, N'dri-Yoman T, Leroy V, Abrams EJ, Rouzioux C, Dabis F.

Clin Infect Dis. 2008 Feb 15;46(4):611-21. doi: 10.1086/526780.

PMID:
18197758
6.
7.

Genotypic resistance tests for the management of the HIV-infected pregnant woman.

Bassetti D, Cargnel A.

Scand J Infect Dis Suppl. 2003;106:70-4. Review.

PMID:
15000589
8.

Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185.

Stiehm ER, Lambert JS, Mofenson LM, Bethel J, Whitehouse J, Nugent R, Moye J Jr, Glenn Fowler M, Mathieson BJ, Reichelderfer P, Nemo GJ, Korelitz J, Meyer WA 3rd, Sapan CV, Jimenez E, Gandia J, Scott G, O'Sullivan MJ, Kovacs A, Stek A, Shearer WT, Hammill H.

J Infect Dis. 1999 Mar;179(3):567-75.

PMID:
9952362
9.

Zidovudine resistance phenotype and risk of perinatal HIV-1 transmission in zidovudine monotherapy-treated mothers with moderately advanced disease.

Bauer GR, Welles SL, Colgrove RR, Pitt J; Women and Infants Transmission Study Team.

J Acquir Immune Defic Syndr. 2003 Nov 1;34(3):312-9.

PMID:
14600578
10.

Efficacy of antenatal zidovudine in reducing perinatal transmission of human immunodeficiency virus type 1. The New York City Perinatal HIV Transmission Collaborative Study Group.

Matheson PB, Abrams EJ, Thomas PA, Hernán MA, Thea DM, Lambert G, Krasinski K, Bamji M, Rogers MF, Heagarty M.

J Infect Dis. 1995 Aug;172(2):353-8.

PMID:
7622877
11.

Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival.

Bardeguez AD, Shapiro DE, Mofenson LM, Coombs R, Frenkel LM, Fowler MG, Huang S, Sperling RS, Cunningham B, Gandia J, Maupin R, Zorrilla CD, Jones T, O'Sullivan MJ; Pediatrics AIDS Clinical Trials Group 288 Protocol Team.

J Acquir Immune Defic Syndr. 2003 Feb 1;32(2):170-81.

PMID:
12571527
12.

Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy.

Clarke JR, Braganza R, Mirza A, Stainsby C, Ait-Khaled M, Wright A, Lyall H, Parker D, McClure MO, Weber JN, Taylor GP.

J Med Virol. 1999 Nov;59(3):364-8.

PMID:
10502270
13.
14.

Prevalence of the T215Y mutation in human immunodeficiency virus type 1-infected pregnant women in a New York cohort, 1995--1999.

Sitnitskaya Y, Rochford G, Rigaud M, Essajee S, Pollack H, Krasinski K, Borkowsky W.

Clin Infect Dis. 2001 Jul 1;33(1):e3-7. Epub 2001 Jun 6.

PMID:
11389511
15.

The effects of zidovudine in the subset of infants infected with human immunodeficiency virus type-1 (Pediatric AIDS Clinical Trials Group Protocol 076).

McSherry GD, Shapiro DE, Coombs RW, McGrath N, Frenkel LM, Britto P, Culnane M, Sperling RS.

J Pediatr. 1999 Jun;134(6):717-24.

PMID:
10356140
16.

Trends in human immunodeficiency virus (HIV) counseling, testing, and antiretroviral treatment of HIV-infected women and perinatal transmission in North Carolina.

Fiscus SA, Adimora AA, Schoenbach VJ, McKinney R, Lim W, Rupar D, Kenny J, Woods C, Wilfert C, Johnson VA.

J Infect Dis. 1999 Jul;180(1):99-105.

PMID:
10353867
17.

Codon 215 mutations in human immunodeficiency virus-infected pregnant women. Swiss Collaborative 'HIV and Pregnancy' Study.

Kully C, Yerly S, Erb P, Kind C, Krautheim A, Perrin L, Rudin C.

J Infect Dis. 1999 Mar;179(3):705-8.

PMID:
9952382
18.

Antiretroviral resistance patterns and HIV-1 subtype in mother-infant pairs after the administration of combination short-course zidovudine plus single-dose nevirapine for the prevention of mother-to-child transmission of HIV.

Chalermchockcharoenkit A, Culnane M, Chotpitayasunondh T, Vanprapa N, Leelawiwat W, Mock PA, Asavapiriyanont S, Teeraratkul A, McConnell MS, McNicholl JM, Tappero JW.

Clin Infect Dis. 2009 Jul 15;49(2):299-305. doi: 10.1086/599612.

PMID:
19522656
19.

Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. Bangkok Collaborative Perinatal HIV Transmission Study Group.

Chuachoowong R, Shaffer N, Siriwasin W, Chaisilwattana P, Young NL, Mock PA, Chearskul S, Waranawat N, Chaowanachan T, Karon J, Simonds RJ, Mastro TD.

J Infect Dis. 2000 Jan;181(1):99-106.

PMID:
10608756
20.

Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.

TEmAA ANRS 12109 Study group, Arrivé E, Chaix ML, Nerrienet E, Blanche S, Rouzioux C, Coffie PA, Kruy Leang S, McIntyre J, Avit D, Srey VH, Gray G, N'Dri-Yoman T, Diallo A, Ekouévi DK, Dabis F.

AIDS. 2009 Apr 27;23(7):825-33. doi: 10.1097/QAD.0b013e32832949d5.

PMID:
19307941

Supplemental Content

Support Center